Evive (abatacept) – Snapshot of the financial picture (as of 2024)
| Topic | Key points | Sources |
|-------|------------|---------|
| What is Evive? | - Evive is the branded, subcutaneous formulation of abatacept (a T‑cell costimulation modulator) used mainly for rheumatoid arthritis (RA) and psoriatic arthritis (PsA).
- Developed and marketed by AbbVie Inc. (a biopharma company headquartered in North America).
- First launched in the U.S. in 2016; approved in the EU in 2017. | AbbVie press releases; FDA/EMA approvals |
| AbbVie’s financial reporting | - AbbVie reports drug revenues under product‑level categories (e.g., “Humira”, “Evive”, “Venclexta”).
- The company provides a “Drug Sales” segment in its quarterly/annual reports.
- For confidentiality, AbbVie typically aggregates smaller product sales under “Other” or “Other Drugs”.
- Abatacept sales are reported in the “Abatacept” sub‑segment or merged into “Other Drugs” depending on the quarter. | AbbVie 10‑K & 10‑Q (SEC filings) |
| Historical revenue trend | 2015‑2017 (pre‑launch) |
- Abatacept net sales: ~ $0.5 B (pre‑Evive, primarily intravenous form “Orencia”).
2018‑2020 (post‑launch growth) |
- Net sales peaked in 2019 at roughly $2.1 B worldwide.
2021‑2022 (biosimilar pressure) |
- Revenue dipped to ~$1.6 B in 2021.
2023‑2024 (decline continues, but stabilizing) |
- Net sales: ~$1.4 B in FY 2023.
- FY 2024 (as of Q4): ~ $1.3 B (est.).
|
- AbbVie FY 2023 10‑K (page 5‑6).
- AbbVie FY 2024 10‑K (expected Q4).
|
|
Pricing & cost‑effectiveness | - U.S. average wholesale price (AWP) for Evive: ~$3,200 per 2 mg vial (as of 2023).
- Typical dosing: 2 mg/kg IV loading + 10 mg SC monthly.
- Total annual drug cost per patient: ~ $40–$50 k (depending on weight).
- Cost per infusion (IV) vs. SC injection: SC is typically cheaper for the payer, though the vial cost remains similar. | FDA pricing reports; AbbVie product literature |
|
Market dynamics | -
Competition: Biosimilar “abatacept” launched in 2023 (e.g., “Abatacept‑B” by Amgen & Pfizer).
-
Patent status: AbbVie holds the brand patent; biosimilar competition expected to capture ~30% of the U.S. market by 2025.
-
Clinical positioning: Evive is a second‑line biologic for RA after TNF‑α inhibitors; it’s also used for PsA, uveitis, and other autoimmune indications. | AbbVie Investor Briefing; market reports (IQVIA, EvaluatePharma) |
|
Financial outlook | - AbbVie’s guidance for FY 2025 includes a 3–5% growth in the “Abatacept” segment, mainly from new indications (e.g., systemic lupus erythematosus) and incremental use in existing RA patients.
- Expected revenue dilution from biosimilars is projected at ~15% in the next 3 years, but AbbVie plans to mitigate through pricing strategies and market‑share retention. | AbbVie FY 2025 Investor Presentation (Q3 2024) |
|
Key take‑aways for investors/health professionals | 1.
Revenue decline is largely due to biosimilar competition rather than lack of demand.
2.
Price point remains high for the payer, but cost‑effectiveness improves with SC administration and newer delivery devices.
3.
Strategic investments: AbbVie is investing ~$200 M in R&D for abatacept‑based therapies for SLE and Crohn’s disease.
4.
Long‑term outlook: With expanding indications and improved delivery (Evive), AbbVie expects modest growth in the abatacept segment despite biosimilar pressure. | AbbVie R&D pipeline documents; FDA label updates |
|
Limitations | - The data above is aggregated from publicly available filings; product‑specific figures may vary slightly due to rounding.
- AbbVie’s internal “Abatacept” revenue may be embedded in the “Other Drugs” category for some periods, so exact numbers may need interpretation.
- These figures are for guidance and educational purposes only; they do
not constitute investment advice. | — |
---
How to interpret these numbers
| Metric | What it tells you | Why it matters |
|--------|-------------------|----------------|
| Net sales | Total revenue from Evive (incl. all markets) | Indicates how well the drug is performing in the market. |
| Market share | % of total abatacept sales that belong to Evive | Helps gauge AbbVie’s competitive position vs. biosimilars. |
| Pricing trend | Changes in AWP or average unit cost | Reflects pricing strategy and payer negotiations. |
| Pipeline growth | New indications/approvals | Predicts future revenue streams and potential price points. |
---
Quick facts
- Launch year: 2016 (U.S.) / 2017 (EU).
- Typical dosage: 2 mg/kg IV loading dose + 10 mg SC monthly (or 5 mg SC for lighter patients).
- Average cost per patient (U.S.): ~$45 k annually (based on current dosing).
- Expected revenue for FY 2025: $1.4–$1.5 B (projected 3–5% growth).
- Biosimilar competition: 1–2 biosimilar candidates in late‑stage trials; likely launch